You are here

  • Home
  • Archive
  • Volume 10, Issue 11
  • Correction: Nemvaleukin Alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Article Text

Article menu

See original article:

Download PDFPDF

Correction
Correction: Nemvaleukin Alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer
Free

https://doi.org/10.1136/jitc-2022-004913corr1

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Pan Y, Hao Y, Han H, et al. Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer. J Immunother Cancer 2022;10:e004913. doi: 10.1136/jitc-2022-004913

    Figure 2 has been updated to resolve an error in section B.